title: Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
abstract: BACKGROUND
  In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases. However, the chronic nature of these diseases requires either prolonged or re-treatment, often with acquired resistance as a consequence.
  
  
  METHODS
  Here we studied the molecular basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examined possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC).
  
  
  RESULTS
  Characterization of BTZ-resistant JY/BTZ cells compared to parental JY/WT cells revealed the following features: (a) 10-12 fold resistance to BTZ associated with the acquisition of a mutation in the PSMB5 gene (encoding the constitutive β5 proteasome subunit) introducing an amino acid substitution (Met45Ile) in the BTZ-binding pocket, (b) a significant 2-4 fold increase in the mRNA and protein levels of the constitutive β5 proteasome subunit along with unaltered immunoproteasome expression, (c) full sensitivity to the irreversible epoxyketone-based PIs carfilzomib and (to a lesser extent) the immunoproteasome inhibitor ONX 0914. Finally, in association with impaired ubiquitination and attenuated breakdown of CD20, JY/BTZ cells harbored a net 3-fold increase in CD20 cell surface expression, which was functionally implicated in conferring a significantly increased anti-CD20/rituximab-mediated CDC.
  
  
  CONCLUSIONS
  These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.
authors.affiliation: Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands. g.jansen@vumc.nl.
authors.forename: Sue Ellen
authors.initials: SE
authors.lastname: Verbrugge
authors.forename: Marjon
authors.initials: M
authors.lastname: Al
authors.forename: Yehuda G
authors.initials: YG
authors.lastname: Assaraf
authors.forename: Denise
authors.initials: D
authors.lastname: Niewerth
authors.forename: Johan
authors.initials: J
authors.lastname: van Meerloo
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Cloos
authors.forename: Michael
authors.initials: M
authors.lastname: van der Veer
authors.forename: George L
authors.initials: GL
authors.lastname: Scheffer
authors.forename: Godefridus J
authors.initials: GJ
authors.lastname: Peters
authors.forename: Elena T
authors.initials: ET
authors.lastname: Chan
authors.forename: Janet L
authors.initials: JL
authors.lastname: Anderl
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kirk
authors.forename: Sonja
authors.initials: S
authors.lastname: Zweegman
authors.forename: Ben Ac
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: Willem F
authors.initials: WF
authors.lastname: Lems
authors.forename: Rik J
authors.initials: RJ
authors.lastname: Scheper
authors.forename: Tanja D
authors.initials: TD
authors.lastname: de Gruijl
authors.forename: Gerrit
authors.initials: G
authors.lastname: Jansen